Glasgow Prognostic Score as a Prognostic Factor for Survival in Chinese Elderly Patients with Colorectal Cancer
Zi-Jian Li,
Qi An,
Jian Cui,
Tao Yu,
Guo-Ju Wu
Issue:
Volume 10, Issue 3, September 2022
Pages:
55-60
Received:
12 December 2021
Accepted:
14 June 2022
Published:
5 July 2022
DOI:
10.11648/j.crj.20221003.11
Downloads:
Views:
Abstract: To investigate the predictive value of Glasgow Prognostic Score (GPS) for the postoperative complications and survival in elderly patients with colorectal cancer (CRC) undergoing radical resection. These participants in Beijing Hospital between February 2009 and November 2011 were included and classified into three groups according to GPS. The GPS was constructed based on C-reactive protein and serum albumin. Univariate and multivariate analyses evaluating predictors of long-term survival were performed. 137 participants were enrolled, including 58 (42.3%) with GPS=0, 64 (46.7%) with GPS=1 and 15 (11.0%) with GPS=2. High GPS group patients were associated with older age (P < 0.001), higher levels of BMI (P = 0.002), higher rate of postoperative complications (P < 0.001), lymph node metastasis (P < 0.001), higher levels of CEA (P < 0.001), CA199 (P = 0.031), as well as more advanced tumor depth and TNM stage (P < 0.001). The 5-year survival rate was 40.9% and 5-year disease-free rate was 51.8%. Univariate and multivariate analyses revealed that GPS, CA199, TNM stage and BMI were independent risk factors of overall survival. Moreover GPS, CA199, TNM stage and BMI were independent risk factors of disease-free survival. The GPS was an independent biomarker to predict long-outcomes of elderly CRC patients undergoing radical resection.
Abstract: To investigate the predictive value of Glasgow Prognostic Score (GPS) for the postoperative complications and survival in elderly patients with colorectal cancer (CRC) undergoing radical resection. These participants in Beijing Hospital between February 2009 and November 2011 were included and classified into three groups according to GPS. The GPS ...
Show More
The Relationship Among Ki-67, ERBB2, GATA3, STAG2, P53, and YAP1 in Pancreatic Ductal Adenocarcinoma
Victoria Hodges,
Christie Fumbah,
Junaith Mohamed,
Sheila Criswell
Issue:
Volume 10, Issue 3, September 2022
Pages:
61-69
Received:
15 June 2022
Accepted:
29 June 2022
Published:
12 July 2022
DOI:
10.11648/j.crj.20221003.12
Downloads:
Views:
Abstract: Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of cancer with a 5-year survival of only 7% for both men and women. Despite substantial progress made in successfully personalizing treatment for other tumors such as breast, prostate, and lung, treatment for PDA remains elusive due, in part, to its unique growth pattern and lack of surveillance tools to detect early lesions. Because most PDA lesions have metastasized at the time of diagnosis and exhibit a heterogeneously infiltrative growth pattern by interdigitating malignant cells among various normal tissue components, decisive, targeted therapies are needed to remove tumor cells while leaving the surrounding benign tissues undamaged. In an effort to identify biomarkers, immunohistochemistry assays were employed to determine the expression of Ki-67, KLK7, YAP1, CK 5, CK 20, CEA, GATA3, XAF1, STAG2, CK 18, ERBB2, and P53 in 42 formalin-fixed, paraffin-embedded PDA samples. Although no statistically significant correlation was associated with tumor aggressiveness as determined by Ki-67 positivity, several pairs of markers demonstrated positive correlations with each other and included ERBB2/STAG2, ERBB/YAP1, ERBB/GATA3, ERBB/P53, GATA3/STAG2, and GATA3/YAP1. Characterization of individual tumors with respect to over- or under-expression of specific proteins may offer dual therapy targets in PDA to potentially improve patient outcomes.
Abstract: Pancreatic ductal adenocarcinoma (PDA) is one of the most lethal forms of cancer with a 5-year survival of only 7% for both men and women. Despite substantial progress made in successfully personalizing treatment for other tumors such as breast, prostate, and lung, treatment for PDA remains elusive due, in part, to its unique growth pattern and lac...
Show More
Anesthesia Management for Awake Craniotomy: Report of Two Cases
Claudia Helena Ribeiro Da Silva,
Luiz Eduardo Imbelloni,
Isabella Cristina Ribeiro Andrade Starling,
Flávia Marques de Melo,
Marluce Marques de Souza
Issue:
Volume 10, Issue 3, September 2022
Pages:
70-74
Received:
5 July 2022
Accepted:
20 July 2022
Published:
5 August 2022
DOI:
10.11648/j.crj.20221003.13
Downloads:
Views:
Abstract: Introduction: Awake craniotomy (AC) started with epilepsy treatment and was extended to other procedures. Several techniques have been used successfully. We will describe show two cases successfully where using the technique with local anesthesia anestesia and sedation protocols were used successfully. Cases Information: The 1st case is a male, 38 years old, 78 kg, ASA II classification, musician, previously healthy when he started with seizures. Imaging tests showed an expansive frontotemporal lesion on the left near the speech region, and tumor resection by awake craniotomy and with a speech monitoring technique in the perioperative period was indicated. At the time of resection, was allowed to play his guitar, with previously with asepsis and permission from the HICC, having been discharged from the ICU on the second day and to residency without neurological deficits. The 2nd was a male patient, 22 years old, 63 kg, 170 cm, with neurofibromatosis with seizures and past thoracolumbar spine arthrodesis brought to operating room due to and tumor recurrence. An MRI of the skull was performed for postoperative control, showed tumor recurrence in an eloquent area, and surgical resection was indicated. After discussing the case with the patient, family members and the anesthetic team, it was decided to perform a craniotomy with the patient awake for better monitoring and safe delimitation of the resection area. The tumor resection was delimited by speech obtaining an almost total resection of the tumor. Conclusion: Based on the report from two cases, AC may have certain benefits for patients undergoing craniotomy, including shorter hospital stay, fewer neurological deficits, and shorter surgery time, with early discharge from the ICU and into residency with their families.
Abstract: Introduction: Awake craniotomy (AC) started with epilepsy treatment and was extended to other procedures. Several techniques have been used successfully. We will describe show two cases successfully where using the technique with local anesthesia anestesia and sedation protocols were used successfully. Cases Information: The 1st case is a male, 38 ...
Show More
